Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Blood Coagul Fibrinolysis ; 5(2): 249-55, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8054458

ABSTRACT

The effect of oral administration of dexamethasone to rats on the haemostatic system was investigated. Dexamethasone was given once daily for 5 consecutive days. Plasma PAI-1 antigen levels were increased dose dependently (up to 210 +/- 29% of control values at a dose of 3 mg/kg) whereas no significant effects on plasma t-PA antigen levels were observed (131 +/- 6% compared with control values). In addition, treatment with 1 mg/kg dexamethasone decreased t-PA activity in tissue extracts of the aorta, heart and liver (65%, 28% and 58%, respectively) whereas tissue u-PA activity was not influenced. In vivo fibrinolytic activity was significantly decreased after dexamethasone treatment at a dose of 3 mg/kg but not at a dose of 1 mg/kg. The effect of dexamethasone on in vivo platelet aggregation was studied in an arterial thrombosis model. Dexamethasone treatment resulted in a two-fold decrease in arterial thrombosis at a dose of 0.1 mg/kg. At a dose of 1 mg/kg a less pronounced but significant decrease was observed. We conclude that in haemostasis the primary effect of dexamethasone treatment is an inhibition of arterial thrombosis by inhibition of platelet aggregation which is neutralized at higher doses by a decreased fibrinolytic activity.


Subject(s)
Dexamethasone/pharmacology , Fibrinolysis/drug effects , Platelet Aggregation/drug effects , Thrombosis/drug therapy , Animals , Aorta , Bleeding Time , Disease Models, Animal , Dose-Response Relationship, Drug , Male , Plasminogen Activator Inhibitor 1/blood , Platelet Aggregation Inhibitors/pharmacology , Rats , Rats, Wistar , Thrombosis/blood , Tissue Plasminogen Activator/blood
2.
Int J Cancer ; 50(4): 507-13, 1992 Feb 20.
Article in English | MEDLINE | ID: mdl-1537614

ABSTRACT

Using viable cells of a human squamous-cell carcinoma (SCC) cell line as immunogen, we generated 2 monoclonal antibodies, MAbs K984 and K928, to SCC surface antigens. Immunoperoxidase staining of frozen sections of normal epidermis revealed that MAb K984 reacts with the poorly differentiated basal cells, while MAb K928 is reactive with the more highly differentiated suprabasal cells. A similar complementary reaction pattern of these antibodies was demonstrated in the majority of well-differentiated human tumors and some moderately differentiated SCCs. In contrast, simultaneous reactivity of MAb K984 and K928 was found for the majority of cells within other well- and moderately differentiated SCCs, as well as all poorly differentiated SCCs. Further biochemical characterization indicated that the antigen recognized by MAb K984 is similar to the one recognized by MAb SF-25. MAb K928 recognizes a 50- to 55-kDa molecule under non-reducing conditions. Antibodies with similar features to MAb K928 have not been described previously. The antigens recognized by MAbs K984 and K928 can be regarded as novel markers associated with cellular maturation in squamous epithelia. The antigen detected by MAb K984 is probably associated with the proliferating fraction in SCCs.


Subject(s)
Antigens, Surface/immunology , Carcinoma, Squamous Cell/immunology , Epithelium/immunology , Antibodies, Monoclonal/immunology , Blotting, Western , Glycoconjugates/immunology , Head and Neck Neoplasms/immunology , Humans , Immunoenzyme Techniques , Molecular Weight , Mouth Mucosa/immunology , Precipitin Tests
3.
Hybridoma ; 9(4): 377-87, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2210778

ABSTRACT

During our efforts to develop monoclonal antibodies (MAbs) to tumor associated surface antigens of squamous cell carcinomas of the head and neck, monoclonal antibody K 931 was produced. The high affinity antibody (Ka 5.0 x 10(10) M-1) showed reactivity with 58 out of 62 squamous cell carcinomas of the head and neck. In contrast normal squamous epithelium as found in epidermis, oral cavity, epiglottis, pharynx, larynx and esophagus did not express the antigen. All other tested epithelial (simple and transitional) tissues did express the antigen, but non-epithelial tissues were negative. Further characterization revealed that the antigen represents the 17-1A antigen. A not earlier reported, enhanced expression of the 17-1A antigen was observed among some primary and all metastatic SCC.


Subject(s)
Antibodies, Monoclonal/biosynthesis , Antigens, Neoplasm/immunology , Carcinoma, Squamous Cell/immunology , Laryngeal Neoplasms/immunology , Animals , Antibodies, Monoclonal/immunology , Antibody Affinity , Antibody Specificity , Carcinoma, Squamous Cell/secondary , Cell Line , Humans , Immunoglobulin Isotypes , Mice , Mice, Inbred BALB C
4.
Int J Cancer ; 46(1): 50-5, 1990 Jul 15.
Article in English | MEDLINE | ID: mdl-2365500

ABSTRACT

Monoclonal antibody (MAb) K 112 was generated after a single intrasplenic immunization with a recurrent laryngeal squamous-cell carcinoma. The antibody detects a 43-kDa nuclear antigen, with a pI of 5.4, which is expressed only in cycling cells. Expression is typically seen in a granular pattern excluding the nucleoli. During mitosis the bulk of the antigen is diffusely distributed in the cytoplasm. Identical reactivity was observed for tissues or cells of all mammalian species tested. These data indicate that MAb K 112 recognizes a protein belonging to the class of cell-cycle-related nuclear antigen molecules.


Subject(s)
Antibodies, Monoclonal , Autoantigens/analysis , Nuclear Proteins/analysis , Animals , Antigens, Nuclear , Carcinoma, Squamous Cell/immunology , Cell Division/immunology , Cell Line , Cell Nucleus/immunology , Cytoplasm/immunology , Hybridomas/immunology , Immunization/methods , Laryngeal Neoplasms/immunology , Mice , Mice, Inbred BALB C , Molecular Weight , Spleen/immunology , Tumor Cells, Cultured/immunology
5.
Arch Otolaryngol Head Neck Surg ; 116(2): 181-5, 1990 Feb.
Article in English | MEDLINE | ID: mdl-2297410

ABSTRACT

For therapeutic or diagnostic use of monoclonal antibodies in clinical oncology, high-affinity IgG antibodies to tumor-associated antigens have to be generated. In order to find out by what immunization schedule the chance to generate such antibodies is increased, we evaluated three different immunization protocols with and without attempts to induce tolerance to common tissue antigens. Mice were immunized either (1) by repeated intraperitoneal injections, (2) by a single intrasplenic injection, or (3) by an intraperitoneal injection followed by an intrasplenic booster. Whereas a single intrasplenic immunization resulted in low-affinity antibodies to tumor-associated antigen, high-affinity antibodies were generated with the other two protocols, although at a lower frequency. No benefit was seen from tolerance induction. The intraperitoneal/intrasplenic protocol was found to be superior over the other protocols because of minimal antigen dose and immunization time, as well as a higher frequency of hybridoma formation.


Subject(s)
Antibodies, Monoclonal/biosynthesis , Antigens, Neoplasm/immunology , Carcinoma, Squamous Cell/immunology , Animals , Antigens, Neoplasm/administration & dosage , Female , Hybridomas , Immunization , Immunohistochemistry , Injections, Intraperitoneal , Mice , Mice, Inbred BALB C
6.
Am J Pathol ; 136(1): 191-7, 1990 Jan.
Article in English | MEDLINE | ID: mdl-2297047

ABSTRACT

After immunization of mice with viable cells of a metastasis of a laryngeal squamous cell carcinoma, a monoclonal antibody E 48 was obtained that detects an epitope present exclusively in squamous and transitional epithelium and their neoplastic counterparts. Immunoblotting revealed that E 48 recognizes a 22 kd molecule. Seventy-five of 76 squamous cell carcinomas from the head and neck, lung, cervix, and skin stained positively, whereas various adenocarcinomas from the colon, lung, and breast, and small cell lung carcinomas consistently stained negatively. The E 48 antigen, which is formaldehyde resistant, appears to be a reliable marker for differentiation of squamous cell carcinomas from adenocarcinoma, and small cell carcinomas.


Subject(s)
Antigens, Surface/analysis , Carcinoma, Squamous Cell/metabolism , Laryngeal Neoplasms/metabolism , Animals , Antibodies, Monoclonal/immunology , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/ultrastructure , Cell Line , Cell Transformation, Neoplastic/immunology , Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/ultrastructure , Epithelium/immunology , Epithelium/metabolism , Epithelium/ultrastructure , Humans , Immunoblotting , Immunohistochemistry , Laryngeal Neoplasms/immunology , Laryngeal Neoplasms/ultrastructure , Mice , Mice, Inbred BALB C , Microscopy, Electron , Neuraminidase/metabolism
7.
Int J Cancer ; 44(3): 534-8, 1989 Sep 15.
Article in English | MEDLINE | ID: mdl-2777416

ABSTRACT

Nude mice carrying human squamous-cell carcinoma xenografts were given i.v. injections of radiolabelled monoclonal antibodies (MAbs). MAb E 48, which reacts with squamous-cell carcinomas, was labelled with 131I, while a second control MAb of similar immunoglobulin subclass was labelled with 125I. Both antibodies were injected simultaneously, then the mice were scanned with a gamma camera or their tissues were removed and antibody uptake was calculated as a percentage of the injected dose. Uptake of E 48 reached a peak value of 16%/g on day 3, while uptake of the control antibody was less than 1.8%/g. By 24 hr after injection tumor could be visualized without subtraction techniques. At days 3 and 7, only xenografts were visible on imaging. These findings suggest that E 48 is capable of high specificity in targeting isotopes to squamous-cell carcinomas in an experimental setting.


Subject(s)
Antibodies, Monoclonal , Carcinoma, Squamous Cell/diagnostic imaging , Head and Neck Neoplasms/diagnostic imaging , Animals , Female , Iodine Radioisotopes , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Transplantation , Radionuclide Imaging , Tissue Distribution , Transplantation, Heterologous
8.
Int J Cancer ; 42(3): 389-94, 1988 Sep 15.
Article in English | MEDLINE | ID: mdl-2458323

ABSTRACT

Resistance to multiple chemotherapeutic agents is a common clinical problem in the treatment of cancer. This resistance may occur before primary therapy or be acquired during treatment. We have generated a monoclonal antibody (MAb) (JSB-I), specific for a conserved epitope on the plasma membrane 170- to 180-kDa glycoprotein, the expression of which is strongly correlated with the degree of multi-drug resistance (MDR). JSB-I strongly binds to both Chinese-hamster-derived MDR cell lines and human MDR cell lines, including cell lines derived from lung and ovary. A drug-sensitive revertant line, and the corresponding drug-sensitive parent lines, showed only weak reactivity or none at all. JSB-I reacts strongly to air-dried or acetone-fixed cells and therefore has potential value for diagnostic detection of MDR cells in human tumor samples.


Subject(s)
Antibodies, Monoclonal , Epitopes/analysis , Membrane Glycoproteins/immunology , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Antibodies, Monoclonal/biosynthesis , Cricetinae , Female , Membrane Glycoproteins/analysis , Mice , Mice, Inbred BALB C , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...